Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Hampshire Health Report.
Press releases published on June 12, 2025
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
GlobeNewswire
·
June 12, 2025
Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0) 48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1) KIT related tolerability events …
DBV Technologies to Participate in Upcoming EAACI Congress 2025
GlobeNewswire
·
June 12, 2025
Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today …
FibroGen Announces 1-for-25 Reverse Stock Split
GlobeNewswire
·
June 12, 2025
SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on …
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
GlobeNewswire
·
June 12, 2025
Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities Of the 64 patients enrolled, 61 received treatment, …
Centurion Service Group to auction all assets following the closure of Rockledge Hospital in Rockledge, FL
GlobeNewswire
·
June 12, 2025
Franklin Park, Illinois, June 12, 2025 (GLOBE NEWSWIRE) -- Centurion Service Group, an industry-leading medical equipment life-cycle company, has been selected to auction all medical and non-medical assets of Rockledge Hospital in Rockledge, FL. All …
Giant-Cell Arteritis Market Heats up with AbbVie’s RINVOQ Approval | DelveInsight
GlobeNewswire
·
June 12, 2025
New York, USA, June 12, 2025 (GLOBE NEWSWIRE) -- Giant-cell Arteritis Market Heats up with AbbVie’s RINVOQ Approval | DelveInsight The FDA has approved AbbVie’s RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved …
First of Its Kind in the Region: KFSHRC Successfully Performs Endoscopic Sleeve Gastroplasty on Kidney Transplant Patient
GlobeNewswire
·
June 12, 2025
RIYADH, Saudi Arabia, June 12, 2025 (GLOBE NEWSWIRE) -- In a medical achievement considered the first of its kind in the region, King Faisal Specialist Hospital …
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
GlobeNewswire
·
June 12, 2025
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML AML patients with diverse mutations, including TP53-mutated/CK and FLT3-wildtype, safely achieved complete …
Apex Labs Granted Israel MoH Approval to Expand Phase 2b Macrodose Psilocybin PTSD Clinical Trial
GlobeNewswire
·
June 12, 2025
Israel’s Ministry of Health (MoH) approval to add additional sites to APEX SUMMIT-90 160 patient phase 2b macrodose clinical trial: Tel Aviv University (TAU)’s Institute for Psychedelic Research located at the Sagol Brain Institute (SGI) in Tel-Aviv …
Implantable Remote Patient Monitoring Devices Market to Grow 21.7% CAGR by 2029
GlobeNewswire
·
June 12, 2025
Boston, June 12, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Global Implantable Remote Patient Monitoring Devices Market” is expected to grow from $7.6 billion in 2024 to $20.3 billion by the end of 2029, at a compound …
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
GlobeNewswire
·
June 12, 2025
Vancouver, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical …
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
GlobeNewswire
·
June 12, 2025
PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for Labcorp (NYSE: LH), a global leader of …
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
GlobeNewswire
·
June 12, 2025
Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: …
Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon
GlobeNewswire
·
June 12, 2025
Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics) Raises full year revenue outlook to $80 - $100 million (excluding ACT Genomics) IM8 contributed $5.7 million in Q1, with $2.8 million in March alone …
Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML)
GlobeNewswire
·
June 12, 2025
WOBURN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, …
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
GlobeNewswire
·
June 12, 2025
Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of …
NewGen Announces Planned US$45 Million Strategic Investment in UAE Real Estate Market
GlobeNewswire
·
June 12, 2025
The Company’s initial investment into the Emirate of Ras Al Khaimah comes ahead of major tourism and infrastructure developments NewGen plans to diversify via additional real estate investments in Abu Dhabi pending potential transactions to provide …
スプリング・バイオ・ソリューション (Spring Bio Solution) 、パラグラフIV証明書を伴う申請 (Para IV Filing) およびファースト・トゥ・ファイル機会を解析するNCEグリッド (NCE Grid) を発表
GlobeNewswire
·
June 12, 2025
ニュージャージー州サマセット発, June 12, 2025 (GLOBE NEWSWIRE) -- コンパレータ調達および治験薬供給のグローバルリーダーであるスプリング・バイオ・ソリューションは、世界初の無料NCE-1インテリジェンス・プラットフォームであり、パラグラフIVおよびNCE-1の機会をリアルタイムで解析・集約・可視化することを目的として構築されたNCEグリッドを発表した。 これまで、NCE独占期間の満了およびパラグラフIV …
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
GlobeNewswire
·
June 12, 2025
PRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) in a mouse …
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
GlobeNewswire
·
June 12, 2025
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data …